Trump administration steers $5B toward AI research

France and other European nations are engaged in ongoing negotiations with U.S. officials to prevent potential trade investigations into their pharmaceutical pricing policies, according to U.S. Trade Representative Jamieson Greer. The discussions come amid heightened scrutiny of how different countries set prices for medicines, with the U.S. threatening to impose tariffs under Section 301 of the Trade Act of 1974, a tool previously used against Germany. In June, the Office of the U.S. Trade Representative initiated an inquiry into Germany's drug pricing mechanisms, marking the first formal step toward possible retaliatory measures. This move has prompted diplomatic efforts by France and other countries to find alternative solutions, avoiding the imposition of tariffs that could strain international economic ties. Greer emphasized during a recent interview that while the U.S. prefers reaching agreements, it retains the option of invoking Section 301 if necessary. The U.S. has already achieved a notable success in securing a commitment from the United Kingdom to increase pharmaceutical spending. An agreement reached in April stipulates that Britain will raise its financial contributions to drug purchases and reduce the rebates available to the National Health Service. This arrangement aims to align British spending patterns more closely with those of the U.S., potentially reducing the need for further punitive action. The Trump administration continues to leverage the threat of tariffs to encourage other nations to adjust their drug pricing strategies. Greer confirmed that the U.S. has been in dialogue with French officials and other governments, though these talks remain complex and evolving. Australia has also been identified as a potential target for a Section 301 probe, highlighting the broad scope of the U.S.’s approach to pharmaceutical pricing globally. European leaders have expressed concern that the U.S.’s focus on drug pricing might undermine broader trade agreements, particularly the recently finalized U.S.-EU trade deal. Signed in Turnberry, Scotland, the agreement includes provisions limiting tariffs on many EU goods to 15 percent. Matthias Jørgensen, the European Commission’s chief trade negotiator on U.S. matters, warned that the current situation could lead to increased tensions within the transatlantic partnership. He noted that recent U.S. actions, including the Section 301 investigation into Germany, pose risks to the stability of the trade relationship. Meanwhile, U.S. lawmakers have shown growing interest in addressing foreign pharmaceutical pricing practices. A group of Senate Republicans recently called on senior administration officials to use Section 301 investigations to secure greater spending on U.S. drugs from international partners. They specifically highlighted Japan for not contributing adequately to the cost of pharmaceutical research and development, suggesting that such issues could become focal points for future negotiations. These developments underscore the increasing complexity of global trade dynamics, particularly in the healthcare sector. As discussions continue, the outcome of these negotiations will likely shape the future of international pharmaceutical policy and trade relations. The next steps will depend on whether the involved parties can reach mutually acceptable agreements or if the threat of tariffs will force changes in national pricing strategies.